HEIDELBERG, 14-Dec-2016 — /EuropaWire/ — Ten life scientists have been awarded EMBO Installation Grants to set up independent research laboratories in the Czech Republic, Estonia, Poland, Portugal and Turkey.
“Through the Installation Grants we encourage some of the best early-career researchers to share their expertise across Europe by setting up laboratories in selected EMBC Member States,” explains EMBO Director Maria Leptin. “Each year, we receive applications from outstanding scientists, and it is a pleasure to be able to support them during this challenging career phase in order to establish scientific excellence across the whole continent.”
Installation Grants are awarded annually. They are funded primarily by the participating member states Czech Republic, Estonia, Poland, Portugal and Turkey. Grantees are selected by a committee of EMBO Members on the basis scientific excellence as the primary selection criterion.
Each Installation Grantee receives 50,000 euros annually for three to five years to support the establishment of an independent research group. In addition to financial support, the recipients receive networking opportunities and practical support by becoming part of the EMBO Young Investigator network.
Since 2006, EMBO has supported 89 group leaders through Installation Grants. Of the most recent awardees, four will establish laboratories in Turkey, two in Poland, two in Portugal, one in Estonia, and one in the Czech Republic.
The next application deadline for EMBO Installation Grants is 15 April 2017.
Name | Research interest | Going to | Coming from |
Melih Acar | Hematopoietic stem cell regulation | Bahcesehir University, School of Medicine, Istanbul, TR | UT Southwestern Medical Center, Dallas, TX, US |
Jaan-Olle Andressoo | Gene knock-up to treat Parkinson’s disease | Tallinn Institute of Technology, EE | University of Helsinki, FI |
Claus Maria Azzalin | Telomeres, cancer and aging | Institute of Molecular Medicine, Lisbon, PT | Institute of Biochemistry, ETH Zurich, CH |
Murat Alper Cevher | Characterization of mediator-estrogen receptor interaction | Bilkent University, Ankara, TR | Rockefeller University, NY, US |
Rafal Ciosk | Cell fate plasticity in development and tissue homeostasis | Institute of Bioorganic Chemistry, Poznan, PL | Friedrich Miescher Institute for Biomedical Research, Basel, CH |
Elif Nur Firat-Karalar | Function and regulation of the centrosome/cilium complex | Koç University, Istanbul, TR | Stanford University, CA, USA |
Catarina Homem | Temporal and metabolic regulation of stem cells | Chronic Diseases Research Center, Nova Medical School, PT | Institute of Molecular Biotechnology of Austria, Vienna, AT |
Abdullah Kahraman | Non-coding cancer driver mutations in isoform networks | Sabanci University, Istanbul, TR | Institute of Molecular Life Sciences, University of Zurich, CH |
Vladimír Varga | Construction of the eukaryotic flagellum | Institute of Molecular Genetics of the ASCR, Prague, CZ | University of Oxford, UK |
Piotr Ziolkowski | Crossover control in plants | Adam Mickiewicz University, Poznan, PL | University of Cambridge, Cambridge, UK |
SOURCE: EMBO
PRESS CONTACT
communications@embo.org
Tilmann KiesslingTilmann Kiessling
Head, Communications
T. + 49 160 9019 3839
(IN BRIEF) Eurex, on April 29, 2024, introduced a new Green Bond Basket within its…
(IN BRIEF) Last Friday, NMB Bank Plc celebrated the listing of its dual-currency sustainability bond,…
(IN BRIEF) CapMan Nordic Infrastructure II fund has reached its final closing at over €375…
(IN BRIEF) AstraZeneca and Daiichi Sankyo's Enhertu, a HER2-directed antibody drug conjugate (ADC), has demonstrated…
(IN BRIEF) AstraZeneca's Truqap, in combination with Faslodex, has received a positive recommendation from the…
(IN BRIEF) Ørsted, a global leader in renewable energy, is divesting its French onshore operations…